Public Sector Pension Investment Board Acquires 7,856 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Public Sector Pension Investment Board grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 8.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,055 shares of the company’s stock after purchasing an additional 7,856 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.22% of Omnicell worth $2,736,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the period. EntryPoint Capital LLC raised its stake in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC boosted its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Benjamin Edwards Inc. grew its stake in Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Omnicell during the 2nd quarter worth $104,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Up 1.6 %

Shares of Omnicell stock opened at $43.02 on Friday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $46.47. The firm’s 50 day moving average price is $40.75 and its 200-day moving average price is $32.77. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a market cap of $1.98 billion, a P/E ratio of -93.52, a PEG ratio of 47.34 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The business’s quarterly revenue was down 7.4% on a year-over-year basis. On average, sell-side analysts predict that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on OMCL. Wells Fargo & Company upped their target price on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Benchmark restated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a report on Monday, July 15th. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Finally, StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $37.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.